BSETrident Texofab LtdHighNeutral
Announced Thu, 13 Nov · 20:10 IST

The Board of Directors inter-alia has approved and taken on record Un-Audited Standalone Financial Results for the quarter and half year ended on September 30, 2025 along with Limited Review ....

Pat Growth 25pctEbitda Margin ExpansionNegative Operating CashflowResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Trident Texofab, a Surat-based grey cloth manufacturer and trader, reported steady topline growth in Q2 FY26. Revenue from operations rose to ₹3,063.46 lakhs, up 15.8% year-on-year, while H1 FY26 revenue grew 12.6% to ₹5,871.14 lakhs. Profit after tax for H1 FY26 jumped 26.1% to ₹214.38 lakhs versus ₹169.98 lakhs in H1 FY25, though other income fell sharply. Q2 standalone PAT stood at ₹112.77 lakhs (vs ₹100.41 lakhs YoY). The auditor (Shah Kailash & Associates LLP) issued an unmodified limited review report. The company operates in a single segment (manufacturing and trading of grey cloth).

Likely market impact

H1 PAT growth of over 25% is a positive signal for shareholders, though the drop in other income and a negative operating cash flow of ₹364.89 lakhs in H1 FY26 (driven by rising trade receivables and loans given) are watchpoints. Stock may see modest positive sentiment on earnings beat, but cash quality of profits remains a concern.